Apolipoprotein E and atherosclerosis: beyond lipid effect.

In humans, apolipoprotein E (apoE) is a polymorphic multifunctional protein.1 It is coded by three alleles (e2, e3, e4) of a modulator gene (level, variability, and susceptibility gene) at the apoE locus on chromosome 19, determining six apoE genotypes and plasma phenotypes. Its pleiotropic effects are exerted on plasma lipoprotein metabolism, coagulation, oxidative processes, macrophage, glial cell and neuronal cell homeostasis, adrenal function, central nervous system physiology, inflammation, and cell proliferation.2,3 ApoE polymorphism modulates susceptibility to many diseases. It is, however, particularly notorious for its role in neurodegenerative disorders4 and atherosclerotic arterial disease.5,6 The e4 allele (phenotypes E4/4 and E4/3) that is associated with higher low density lipoprotein cholesterol (LDL-C) is considered proatherogenic, whereas the presence of the e2 allele (E3/2, E2/2), being associated with lower LDL-C levels, is deemed to have the opposite effect (although it may be associated with increased plasma triglycerides and lipoprotein remnants). This simple equation, however, is an oversimplification because these properties are subject to many environmental and genetic influences. ApoE has allele- and gender-dependent effects on reverse cholesterol transport, platelet aggregation, and oxidative processes that are likely to affect the overall atherogenic potential ascribed to modulation of lipoprotein metabolism.2,3,6 Notwithstanding the context dependency, a recent meta-analysis fully supports the presence of the e4 allele as a significant risk factor for coronary artery disease.7 Several mechanisms have been evoked to link apoE with atherosclerosis, but the relationship is not fully unraveled in humans. Nevertheless, some apoE mimetic peptides that promote LDL clearance are currently tested in animals for potential clinical applications.8,9 See page 436 The situation is relatively simpler in animals. The mouse model has been prominently useful to test mechanisms …

[1]  S. Fazio,et al.  Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation , 1995, Science.

[2]  D. Rader,et al.  Reduction of Isoprostanes and Regression of Advanced Atherosclerosis by Apolipoprotein E* , 2001, The Journal of Biological Chemistry.

[3]  P. Nihoyannopoulos,et al.  Uses and limitations of high dose dipyridamole stress echocardiography for evaluation of coronary artery disease. , 1992, British heart journal.

[4]  Meir J Stampfer,et al.  Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease , 2004, Annals of Internal Medicine.

[5]  E. Fisher,et al.  Subphysiologic Apolipoprotein E (ApoE) Plasma Levels Inhibit Neointimal Formation After Arterial Injury in ApoE-Deficient Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  L. Havekes,et al.  Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. , 1997, Atherosclerosis.

[7]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[8]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[9]  R. Walzem,et al.  Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  G. Anantharamaiah,et al.  Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. , 2003, Atherosclerosis.

[11]  L. Curtiss,et al.  An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. , 1998, The Journal of clinical investigation.

[12]  M. Gotthardt,et al.  LRP and PDGF signaling: a pathway to atherosclerosis. , 2004, Trends in cardiovascular medicine.

[13]  D. Rader,et al.  Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  L. Bernier,et al.  Apolipoprotein E and atherosclerosis: insight from animal and human studies. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[15]  R. Mahley,et al.  Apolipoprotein E. Structure, Function, and Possible Roles in Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[16]  L. Curtiss.  ApoE in atherosclerosis : a protein with multiple hats. , 2000, Arteriosclerosis, Thrombosis and Vascular Biology.

[17]  Q. Yao,et al.  Cellular and molecular mechanisms of atherosclerosis with mouse models. , 2004, Trends in cardiovascular medicine.

[18]  R. Raffai,et al.  Apolipoprotein E Promotes the Regression of Atherosclerosis Independently of Lowering Plasma Cholesterol Levels , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  K. Weisgraber,et al.  Hypomorphic Apolipoprotein E Mice , 2002, The Journal of Biological Chemistry.

[20]  K. Imaizumi,et al.  Dietary soy protein isolate, compared with casein, reduces atherosclerotic lesion area in apolipoprotein E-deficient mice. , 1998, The Journal of nutrition.